Research & Development

Developing the leading the treatment of adenoviral conjunctivitis

We are a clinical stage ophthalmic specialty biotechnology company.

We are exclusively focused on developing the leading treatment of adenoviral conjunctivitis (also known as pink eye).

Our lead product candidate, OKG-0502, is a topical, eye drop formulation of an anti-viral medication with an ocular decongestant. 

Dig Deeper into our Research & Development

Adenoviral Conjunctivitis

Information About this Condition

RUBY Trial

Our Lead Clinical Program